Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer

BACKGROUND: The multicenter, open‐label, randomized, phase III EPIC study (EMR 062202‐025) investigated cetuximab plus irinotecan versus irinotecan in patients with epidermal growth factor receptor–detectable metastatic colorectal cancer (mCRC) that progressed on first‐line fluoropyrimidine‐ and oxa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Sobrero, Alberto, Lenz, Heinz‐Josef, Eng, Cathy, Scheithauer, Werner, Middleton, Gary, Chen, Wenfeng, Esser, Regina, Nippgen, Johannes, Burris, Howard
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2020
Témata:
Gastrointestinal Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873334/
https://ncbi.nlm.nih.gov/pubmed/33191588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13591
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky